Mesa Laboratories, Inc. (MLAB)
NASDAQInformation TechnologyMedical - SpecialtiesSnapshot 2026-09-04
$127.78-0.58%
Close 2026-09-04 · 1-day change
NASDAQInformation TechnologyMedical - SpecialtiesSnapshot 2026-09-04
Broken: Primary pillar broken — EPS grows to at least $11.6 in FY27: FY27 EPS $9.95 vs $11.6 target.
Mesa Laboratories grew revenue 3.4% in fiscal 2026 to $249 million. Earnings per share estimates rose to $11.62 for fiscal 2027. The company has a strong profit margin with a PE of 19.7, well below peers. Free cash flow yield is 7%, supporting capital return.
CEO transition in early 2026 creates uncertainty. The company drew $108 million on its credit facility, increasing leverage. Revenue growth is modest at 3.4%, below some peers. The stock has fallen 12% from highs, reflecting risk.
The stock trades about 24% below our $130 fair value. Analysts expect 5.2% revenue growth, slightly above recent 3.4%. Our view is more optimistic on earnings growth and margin stability.
Breaks if: debt exceeds $110 million
Breaks if: EPS falls below $11.6 in FY27
Breaks if: organic revenue growth falls below 3% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
MLAB represents a durable compounder in the tech sector. The company has shown strong recent financial performance, but it faces elevated risks that could impact its trajectory.
The current valuation suggests that the market views MLAB as relatively cheap compared to its peers. There is a slight expectations gap, indicating that the market may not fully account for potential positive developments.
Management is focused on returning to positive core organic growth and achieving specific revenue targets. Recent results show that they are on track to meet these goals, although there is a risk of missing expectations due to the company's smaller size and the industry's high miss rate.
The future performance of MLAB will depend on management's ability to maintain growth momentum and navigate potential risks. Key factors include guidance updates, interest rate changes, and performance from sector leaders like NVDA and AMD.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. Margin expansion supports the goal to reduce total net leverage below 2.0. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: PE rises above 30 without margin improvement
Over the next 1 to 3 years, MLAB's performance will be influenced by its ability to execute on growth strategies and external market conditions. Not investment advice.